Checkmate Pharmaceuticals CMPI

$ 10.5 0.0%

Quarterly report 2022-Q1
added 12-23-2023

Checkmate Pharmaceuticals Income Statement 2011-2024 | CMPI

Annual Income Statement Checkmate Pharmaceuticals

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	52.7 M	213 M	-	-	-	-	-	-	-	-	-
Shares	21.6 M	13.6 M	-	-	-	-	-	-	-	-	-
Historical Prices	2.44	15.7	-	-	-	-	-	-	-	-	-
Net Income	-61.4 M	-36.9 M	-28.3 M	-20.8 M	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-61.5 M	-36.9 M	-28.9 M	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-61.4 M	-36.9 M	-28.9 M	-21 M	-	-	-	-	-	-	-
Operating Expenses	61.5 M	36.9 M	28.9 M	21 M	-	-	-	-	-	-	-
General and Administrative Expenses	15.7 M	10.2 M	4.64 M	2.82 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Checkmate Pharmaceuticals

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	-	-	-	21.6 M	21.6 M	21.6 M	21.6 M	21.6 M	21.6 M	13.6 M	1.49 M	1.49 M	1.49 M	1.49 M	1.43 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-	-	-	-15.9 M	-	-15 M	-19 M	-14.1 M	-	-9.83 M	-8.35 M	-7.8 M	-	-6.24 M	-6.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-	-	-	-15.9 M	-	-15 M	-19 M	-14.2 M	-	-9.83 M	-8.27 M	-7.82 M	-	-6.28 M	-6.96 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-15.8 M	-	-15 M	-19 M	-14.2 M	-	-9.83 M	-8.27 M	-7.82 M	-	-6.28 M	-6.96 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	15.9 M	-	15 M	19 M	14.2 M	-	9.83 M	8.27 M	7.82 M	-	6.28 M	6.96 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	-	-	-	4.24 M	-	3.6 M	4.09 M	3.8 M	-	3.16 M	1.8 M	1.51 M	-	1.21 M	1.11 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency